Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
The Patent (Amendment) Rules, 2024: What the New Flexibility Gives You — and the Hard Deadlines It Cannot Touch
Introduction On 15 March 2024, the Patent (Amendment) Rules, 2024 came into force and quietly rewrote the rhythm of patent prosecution in India. Practitioners who had spent two decades telling clients "this deadline cannot be extended, full stop" suddenly found themselves revising standard advice: many timelines that were once immovable can now be bought back, at a price, under the liberalised Rule 138. But here lies the trap — and it is a trap that has already caught applicants who read the headlines and not the fine print. The 2024 amendments are subordinate legislation made under Section 159 of the Patents Act, 1970. They can soften only those timelines that live in the Rules . Where the Act itself fixes a period and attaches a consequence — "deemed abandoned," "deemed withdrawn," "shall not be entertained" — no Rule, however generously worded, can rescue a defaulting applicant. Only Parliament can. This article does two things. First, it wal...